Company news

Inovio Pharmaceuticals, Inc. news in 2024

Inovio Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

INOVIO Announces Pricing of $30 Million Public Offering

December 12, 2024

New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial

December 2, 2024

INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights

November 13, 2024

Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial

November 12, 2024

INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024

November 5, 2024

INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP

October 20, 2024

INOVIO Reports Inducement Grants Under Inducement Plan

October 1, 2024

INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights

August 7, 2024

INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024

July 24, 2024

Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107

July 24, 2024

INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway

July 10, 2024

INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer

July 1, 2024

INOVIO Added to Russell 2000® Index Effective July 1, 2024

June 30, 2024

INOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc.

June 3, 2024

INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 12, 2024

INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024

April 28, 2024

INOVIO to Participate in Upcoming Investor Conferences in May

April 28, 2024

INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

April 14, 2024

INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine

March 25, 2024

INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

March 5, 2024

Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting

March 5, 2024

INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024

February 20, 2024

INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 6, 2024

INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split

January 22, 2024

INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader

January 21, 2024

INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)

January 3, 2024

INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program

January 2, 2024

Calls in 2024

Decks in 2024